MDT-AP-0725
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 72.96000000000001
- os_event
- true
- age_years
- 18
- sex
- M
- new_clusters
- S1
- umap1_2d
- -1.497500876
- umap2_2d
- -11.00773993
- umap1_3d
- -2.313088833
- umap2_3d
- -0.690423639
- umap3_3d
- 5.170483827
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- PANCREAS_BETA_CELLS+0.400
- TNFA_SIGNALING_VIA_NFKB+0.380
- ALLOGRAFT_REJECTION+0.280
- APOPTOSIS+0.240
- COAGULATION+0.230
- INFLAMMATORY_RESPONSE+0.220
- ESTROGEN_RESPONSE_LATE+0.210
- INTERFERON_GAMMA_RESPONSE+0.210
- KRAS_SIGNALING_DN+0.210
Top 10 suppressed
- PROTEIN_SECRETION-0.340
- PI3K_AKT_MTOR_SIGNALING-0.320
- DNA_REPAIR-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.280
- MITOTIC_SPINDLE-0.250
- HEME_METABOLISM-0.230
- OXIDATIVE_PHOSPHORYLATION-0.230
- TGF_BETA_SIGNALING-0.210
- MTORC1_SIGNALING-0.170
- FATTY_ACID_METABOLISM-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2576 | Med | Medulloblastoma | 0.841 |
| 2 | MDT-AP-2495 | Med | Medulloblastoma | 0.825 |
| 3 | MDT-AP-2284 | Med | Medulloblastoma | 0.811 |
| 4 | MDT-AP-2621 | Med | Medulloblastoma | 0.811 |
| 5 | MDT-AP-1406 | Med | Medulloblastoma | 0.803 |
| 6 | MDT-AP-0446 | Med | Medulloblastoma | 0.798 |
| 7 | SRR1442666 | GTEX | — | 0.794 |
| 8 | MNG1166 | — | — | 0.794 |
| 9 | SRR1071289 | GTEX | — | 0.788 |
| 10 | SRR1445238 | GTEX | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |